Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Christensen DP, Dahllöf M, Lundh M, Rasmussen DN, Nielsen MD, Billestrup N, Grunnet LG, Mandrup-Poulsen T.

Mol Med. 2011 May-Jun;17(5-6):378-90. doi: 10.2119/molmed.2011.00021. Epub 2011 Jan 25. Review.

2.

The oral histone deacetylase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro.

Lewis EC, Blaabjerg L, Størling J, Ronn SG, Mascagni P, Dinarello CA, Mandrup-Poulsen T.

Mol Med. 2011 May-Jun;17(5-6):369-77. doi: 10.2119/molmed.2010.00152. Epub 2010 Dec 22.

3.

Small-Molecule Suppressors of Cytokine-Induced beta-Cell Apoptosis.

Chou DH, Bodycombe NE, Carrinski HA, Lewis TA, Clemons PA, Schreiber SL, Wagner BK.

ACS Chem Biol. 2010 Aug 20;5(8):729-34. doi: 10.1021/cb100129d.

4.

Chemical phylogenetics of histone deacetylases.

Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R.

Nat Chem Biol. 2010 Mar;6(3):238-243. Epub 2010 Feb 7.

5.

Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells.

Grunnet LG, Aikin R, Tonnesen MF, Paraskevas S, Blaabjerg L, Størling J, Rosenberg L, Billestrup N, Maysinger D, Mandrup-Poulsen T.

Diabetes. 2009 Aug;58(8):1807-15. doi: 10.2337/db08-0178. Epub 2009 May 26.

6.

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Methot JL, Chakravarty PK, Chenard M, Close J, Cruz JC, Dahlberg WK, Fleming J, Hamblett CL, Hamill JE, Harrington P, Harsch A, Heidebrecht R, Hughes B, Jung J, Kenific CM, Kral AM, Meinke PT, Middleton RE, Ozerova N, Sloman DL, Stanton MG, Szewczak AA, Tyagarajan S, Witter DJ, Secrist JP, Miller TA.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):973-8. doi: 10.1016/j.bmcl.2007.12.031. Epub 2008 Jan 7.

PMID:
18182289
7.

Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation.

Fornoni A, Pileggi A, Molano RD, Sanabria NY, Tejada T, Gonzalez-Quintana J, Ichii H, Inverardi L, Ricordi C, Pastori RL.

Diabetologia. 2008 Feb;51(2):298-308. Epub 2007 Dec 8.

PMID:
18066521
8.

Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells.

Larsen L, Tonnesen M, Ronn SG, Størling J, Jørgensen S, Mascagni P, Dinarello CA, Billestrup N, Mandrup-Poulsen T.

Diabetologia. 2007 Apr;50(4):779-89. Epub 2007 Jan 31.

PMID:
17265033
9.

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Minucci S, Pelicci PG.

Nat Rev Cancer. 2006 Jan;6(1):38-51. Review.

PMID:
16397526
10.

Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2.

Miret S, De Groene EM, Klaffke W.

J Biomol Screen. 2006 Mar;11(2):184-93. Epub 2005 Nov 28.

PMID:
16314402
11.

Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities.

Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL.

Diabetes. 2005 Dec;54 Suppl 2:S97-107. Review.

12.

Glucose sensitivity and metabolism-secretion coupling studied during two-year continuous culture in INS-1E insulinoma cells.

Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P.

Endocrinology. 2004 Feb;145(2):667-78. Epub 2003 Oct 30.

PMID:
14592952
13.
14.

Mitochondrial membrane potential monitored by JC-1 dye.

Reers M, Smiley ST, Mottola-Hartshorn C, Chen A, Lin M, Chen LB.

Methods Enzymol. 1995;260:406-17. No abstract available.

PMID:
8592463
15.

Cytotoxic effect of IFN-gamma plus TNF-alpha on human islet cells.

Soldevila G, Buscema M, Doshi M, James RF, Bottazzo GF, Pujol-Borrell R.

J Autoimmun. 1991 Apr;4(2):291-306.

PMID:
1909137

Supplemental Content

Support Center